Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers.

Stangier, J; Su, C A; Brickl, R; Franke, H

Stangier, J; Su, C A; Brickl, R; Franke, H.

Affiliation

Stangier J; Department of Pharmacokinetics and Drug Metabolism, Boehringer Ingelheim Pharma KG, Birkendorfer Strasse, D-88397 Biberach an der Riss, Germany.

J Clin Pharmacol ; 40(12 Pt 1): 1365-72, 2000 Dec.

Article in En | MEDLINE | ID: mdl-11185635

Subject(s)

Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics; Benzimidazoles/pharmacokinetics; Benzoates/pharmacokinetics; Renal Dialysis; Renal Insufficiency/metabolism; Adult; Angiotensin-Converting Enzyme Inhibitors/administration & dosage; Angiotensin-Converting Enzyme Inhibitors/adverse effects; Angiotensin-Converting Enzyme Inhibitors/blood; Benzimidazoles/administration & dosage; Benzimidazoles/adverse effects; Benzimidazoles/blood; Benzoates/administration & dosage; Benzoates/adverse effects; Benzoates/blood; Female; Humans; Kidney/metabolism; Male; Middle Aged; Protein Binding; Renal Insufficiency/therapy; Telmisartan

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Benzimidazoles / Benzoates / Angiotensin-Converting Enzyme Inhibitors / Renal Dialysis / Renal Insufficiency Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Clin Pharmacol Year: 2000 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links